Home / Peptides / Tesamorelin

Tesamorelin

A synthetic GHRH analog developed for HIV-associated lipodystrophy. FDA-approved for specific clinical use in reducing visceral adiposity. Comprehensive research overview and mechanism of action.

GHRH Analog | FDA-Approved | Research Education
Plain-English Summary

A GHRH analog that is FDA-approved (as Egrifta) for one specific use: reducing excess abdominal fat in HIV-associated lipodystrophy. Off-label research interest focuses on GH optimization and visceral fat reduction.

Why people are looking into this peptide

What people typically want from it

People researching Tesamorelin are usually interested in visceral fat reduction and growth hormone optimization. They typically want to:

  • Reduce stubborn belly fat (especially visceral fat around the organs)
  • Improve body composition without changing diet or exercise dramatically
  • Support healthy GH and IGF-1 levels
  • Address HIV-associated lipodystrophy (the one FDA-approved indication)
  • Improve metabolic markers like triglycerides

Plain-English reasons people explore this peptide in research settings. Not medical advice. See Studied Benefits below for the published-research view.

Quick Reference. Tesamorelin

Studied Benefits

  • Reduction in visceral adipose tissue (VAT) in HIV lipodystrophy (FDA-approved indication)
  • Elevated IGF-1 levels (50-100% increase from baseline)
  • Improved abdominal circumference measurements
  • Increased lean body mass in clinical trials
  • Investigational effects on cognitive function and liver fat reduction (NAFLD)

Protocol At-a-Glance

Common Starting Dose 2 mg
Studied Range 2 mg daily (FDA-approved dose)
Frequency Once daily
Timing Evening preferred (aligns with natural GH pulse)
Fasting At least 30 minutes before eating
Reconstitution Sterile water provided in kit; specific volume varies by formulation
Storage Egrifta (original): 2-8°C. Egrifta SV: room temp (15-30°C), use within 28 days after reconstitution
Typical Cycle Ongoing therapy as prescribed (FDA-approved continuous use)
Route SubQ injection
Start Low, Go Slow: Tesamorelin is an FDA-approved therapeutic requiring medical oversight. Any research or investigational use should begin at conservative doses and be monitored carefully. IGF-1 levels should be monitored regularly to ensure they remain within physiologic ranges. This is not medical advice. Consult a licensed healthcare professional before considering any tesamorelin protocol.

Overview

Tesamorelin (brand names: Egrifta and Egrifta SV) is a synthetic 44-amino acid analog of growth hormone-releasing hormone (GHRH), developed by Theratechnologies Inc. It is the only FDA-approved GHRH analog currently available in the United States.

Tesamorelin was specifically approved for reducing excess abdominal fat (visceral adiposity) in HIV-positive patients with lipodystrophy-a metabolic complication associated with antiretroviral therapy. The distinction between tesamorelin and other growth hormone secretagogues lies in its clinical evidence base and regulatory approval for this specific indication.

44
Amino Acids
~26 min
Serum Half-Life
2010
FDA Approval Year
2mg
Clinical Dose

Key Distinction: Endogenous vs. Exogenous GH

Tesamorelin works by stimulating the patient's own pituitary gland to produce and release growth hormone. This is mechanistically distinct from direct exogenous GH administration. By preserving the natural pulsatile pattern of GH secretion and the negative feedback loop, tesamorelin maintains physiologic GH homeostasis while avoiding the suppression of endogenous GH production that occurs with exogenous GH injection.

Educational Context: Understanding the mechanism of GHRH analogs is important for research into growth hormone physiology, metabolic dysfunction in chronic disease, and the differential effects of stimulating endogenous hormone production versus direct hormone replacement.

FDA Status & Regulatory Approval

FDA-Approved November 2010 (Original Egrifta)

Approved Indication

Tesamorelin is approved by the FDA exclusively for reducing excess abdominal fat (visceral adipose tissue) in HIV-positive patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by abnormal fat redistribution that occurs in some patients undergoing antiretroviral therapy.

The approval was based on clinical trial data showing significant reduction in visceral adipose tissue (VAT) compared to placebo in this specific population. This targeted approval reflects the clinical evidence generated during the drug's development.

Egrifta SV (2019 Reformulation)

In 2019, the FDA approved Egrifta SV, a reformulated version of tesamorelin with improved stability. This version is room-temperature stable and does not require refrigeration, making it more convenient for patients and researchers.

Critical Distinction: Tesamorelin is NOT approved for:
  • General weight loss or obesity management
  • Anti-aging applications
  • Bodybuilding or athletic enhancement
  • Growth hormone optimization in non-lipodystrophic populations
  • Cognitive enhancement or neurological disorders

Off-label use exists in research and clinical contexts but is a separate regulatory and medical consideration.

Off-Label Research Context

While tesamorelin's FDA approval is limited to HIV lipodystrophy, the scientific literature includes investigational studies examining its effects on other conditions. These studies explore potential applications in body composition, cognitive function in aging, and liver fat reduction (NAFLD/MASH), but these remain investigational uses without regulatory approval.

Mechanism of Action

GHRH Receptor Agonism

Tesamorelin functions as a growth hormone-releasing hormone (GHRH) receptor agonist. It binds to GHRH receptors located on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and secretion of growth hormone.

This binding event triggers a cascade of intracellular signaling that results in:

  • GH synthesis and secretion: Increased production of endogenous GH from pituitary somatotrophs
  • IGF-1 elevation: Elevated circulating IGF-1 concentrations (typically 50-100% increase from baseline)
  • Metabolic effects: Changes in fat metabolism and body composition through GH/IGF-1 axis signaling

Preservation of Physiologic Pulsatility

A critical distinction from exogenous GH: tesamorelin preserves the natural pulsatile pattern of growth hormone secretion and maintains the body's negative feedback loops. The hypothalamic-pituitary-GH axis continues to function normally, with somatostatin and GHRH providing endogenous regulation. This contrasts with exogenous GH administration, which can suppress endogenous GH production and disrupt normal pulsatile secretion patterns.

Pharmacokinetic Profile

  • Serum half-life: Approximately 26 minutes
  • Route: Subcutaneous injection
  • Clinical half-life: Despite rapid serum clearance, GH-releasing effects persist longer, supporting once-daily dosing
  • Peak effects: GH levels typically peak 2-4 hours post-injection
Research Context: The pharmacokinetics of tesamorelin are relevant to understanding how GHRH analogs differ from direct GH supplementation and how stimulating hormone release through receptor agonism creates a different physiologic profile than replacement therapy.

Clinical Trial Data & Evidence

HIV Lipodystrophy Studies

REDUCE Trial (Phase 3): This landmark study demonstrated significant reduction in visceral adipose tissue (VAT) in HIV-positive patients with lipodystrophy receiving tesamorelin compared to placebo. Multiple Phase 3 trials showed VAT reductions of 15-18% from baseline in this population.

Key findings included:

  • Significant reduction in visceral fat mass (primary endpoint)
  • Improvements in abdominal circumference
  • Elevated IGF-1 levels (mean increase ~50-100% from baseline)
  • Improvements in some metabolic markers
  • Increased lean body mass in some studies

Investigational Studies

Cognitive Function in Older Adults: Several investigational studies have examined tesamorelin's effects on cognitive function and brain health in aging populations. Makimura et al. and colleagues have published research on this topic, examining GH axis effects on cognition, though these remain investigational and are not part of the approved indication.

NAFLD/MASH Research: Some research has examined tesamorelin's effects on liver fat accumulation and non-alcoholic fatty liver disease, exploring whether GH elevation can reduce hepatic steatosis. This research is ongoing and investigational.

Body Composition & Metabolic Studies: Additional studies in non-HIV populations have examined tesamorelin's effects on body composition, lean mass, and metabolic parameters, though these are distinct from the approved clinical indication.

IGF-1 Response

IGF-1 elevation is a consistent finding across tesamorelin studies, with mean increases of 50-100% from baseline typically observed. IGF-1 monitoring is recommended during therapy to ensure physiologic GH stimulation and to monitor for potential adverse effects related to elevated IGF-1.

Important Note: Clinical trial data supporting tesamorelin's approval focuses on its safety and efficacy for HIV lipodystrophy. Investigational studies examining other indications represent ongoing research and should not be interpreted as evidence of efficacy or safety for those conditions.

Dosing & Administration

FDA-Approved Dosing

  • Dose: 2 mg subcutaneous injection once daily
  • Route: Subcutaneous injection
  • Administration site: Typically abdomen (may rotate injection sites)
  • Reconstitution: Powder reconstituted with sterile water provided in the kit
  • Frequency: Once daily, preferably at the same time each day

Administration Procedure (General Research Context)

Tesamorelin is supplied as a lyophilized powder that requires reconstitution before injection. The reconstitution process involves:

  1. Withdrawing the specified volume of sterile water
  2. Slowly injecting the water into the vial containing the lyophilized tesamorelin
  3. Gently swirling (not shaking) to dissolve the powder
  4. Allowing the solution to clear
  5. Withdrawing the appropriate dose for subcutaneous injection

Storage Considerations

  • Egrifta (original): Requires refrigeration at 2-8°C
  • Egrifta SV: Room-temperature stable, can be stored at 15-30°C (59-86°F)

Side Effects & Safety Profile

Adverse Events from Clinical Trial Data

The following table summarizes adverse events reported in clinical trials of tesamorelin in HIV-lipodystrophy patients. Unlike many investigational peptides, tesamorelin has FDA-approved clinical trial data with documented incidence rates. Reported incidence is from Phase 3 clinical trials conducted during regulatory approval processes.

Side Effect Reported Incidence Severity Commonly Reported Mitigation Strategies
Injection site reactions (erythema, pruritus, pain, irritation) 24.5% in clinical trials Mild Rotate injection sites between abdomen areas, allow solution to reach room temperature before injection
Arthralgia (joint pain) 13.3% in clinical trials Mild-Moderate Stay well-hydrated, gentle stretching, may resolve with continued use
Injection site erythema specifically 8.5% in clinical trials Mild Apply ice briefly before injection, rotate sites
Pain in extremities 6.1% in clinical trials Mild Often related to GH-induced fluid retention; adequate hydration and electrolytes
Peripheral edema (swelling) 6.1% in clinical trials Mild-Moderate Monitor sodium intake, elevate affected extremities, adequate water intake
Myalgia (muscle pain) 4.1% in clinical trials Mild Gentle activity, hydration, typically resolves within first few weeks
Pruritus (itching at injection site) 3.4% in clinical trials Mild Rotate injection sites, avoid injecting into irritated skin
Nausea 2.7% in clinical trials Mild Administer in a fasted state or before bed
Carpal tunnel symptoms ~2% (related to GH elevation) Moderate Often dose-dependent; may resolve if dose is reduced; wrist splinting
Hyperglycemia risk Documented in clinical trials Moderate Monitor blood glucose regularly, particularly for those with pre-existing insulin resistance

Important Note on Mitigation Strategies: These mitigation strategies are commonly discussed in research literature and clinical practice. They do not constitute medical advice. Consult a healthcare professional regarding any concerns about side effects or mitigation approaches.

Contraindications & Precautions

Absolute contraindications include:

  • Active malignancy or history of malignancy (relative contraindication)
  • Known hypersensitivity to tesamorelin or any component
  • Disruption of the hypothalamic-pituitary axis (pituitary surgery, radiation, tumors)
  • Pregnancy

Monitoring recommendations:

  • Regular IGF-1 level monitoring
  • Blood glucose monitoring in patients with diabetes or glucose intolerance
  • Assessment for signs of carpal tunnel syndrome
  • Evaluation of injection sites for reactions or lipohypertrophy

IGF-1 Monitoring

IGF-1 elevation is an expected pharmacologic effect of tesamorelin. However, IGF-1 levels should be monitored to ensure they remain within physiologic ranges and to assess for potential adverse effects associated with elevated IGF-1 (such as increased risk of malignancy, carpal tunnel syndrome, or joint pain).

Safety Note: Because tesamorelin elevates GH and IGF-1, there are theoretical concerns regarding malignancy risk (as with any GH therapy). Patients with active or prior malignancy should be carefully evaluated before tesamorelin use. The clinical significance of modestly elevated IGF-1 from tesamorelin is distinct from the marked elevations seen with pharmacologic GH supplementation.

Tesamorelin vs. Other GH Secretagogues

Parameter Tesamorelin CJC-1295 Ipamorelin Exogenous GH
Drug Class GHRH analog GHRH analog (modified) GHS (secretagogue) Recombinant hormone
FDA Approval Status FDA-Approved (HIV lipodystrophy) Not FDA-approved Not FDA-approved FDA-approved (multiple indications)
Receptor Target GHRH receptor GHRH receptor Ghrelin receptor GH receptor (direct)
Mechanism Pituitary GH release stimulation Pituitary GH release stimulation Pituitary GH release stimulation Direct GH action
Endogenous GH Suppression No (preserves feedback) No (preserves feedback) No (preserves feedback) Yes (suppresses endogenous GH)
Clinical Evidence Base Strong (Phase 3 trials) Limited/Investigational Limited/Investigational Strong (decades of use)
Half-Life ~26 minutes (serum) Variable (modified analogs) ~2 hours ~20 minutes
Frequency Once daily Variable (weekly/bi-weekly) Variable (typically 3x/week) 1-7x/week depending on indication

Research Context: Why the Regulatory Distinction Matters

Tesamorelin holds FDA approval specifically for HIV lipodystrophy based on Phase 3 clinical trial data. Other GH secretagogues (CJC-1295, Ipamorelin) do not have FDA approval but are studied in various research contexts. Exogenous GH has extensive FDA approvals but works through a different mechanism-direct hormone replacement rather than stimulating endogenous production.

In research contexts, tesamorelin is often distinguished as the only GHRH analog with clinical approval, giving it a unique regulatory status. Studies combining tesamorelin with other secretagogues (such as Ipamorelin or CJC-1295) exist in the literature, exploring potential synergistic effects on GH stimulation, but such combinations are investigational.

Off-Label Research & Investigational Uses

While tesamorelin's FDA approval is limited to HIV lipodystrophy, the scientific literature explores its potential in other conditions. It is important to emphasize that these remain investigational uses without regulatory approval:

Body Composition & Metabolic Improvement

Research examining tesamorelin's effects on lean body mass, fat mass, and metabolic parameters in non-HIV populations. These studies explore whether GH stimulation can improve body composition independent of lipodystrophy.

Cognitive Function & Brain Health

Investigational studies have examined the effects of GH axis modulation on cognitive performance and neurological outcomes in aging populations. The rationale is based on GH's known effects on brain health and neuroplasticity, but these applications remain experimental.

NAFLD & Liver Fat Reduction

Some research has investigated whether tesamorelin can reduce hepatic steatosis in non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated fatty liver disease (MAFLD). The mechanism would involve GH's effects on lipid metabolism and hepatic insulin sensitivity.

Off-Label Clarification: Off-label use of approved medications is a clinical/research decision made by physicians and researchers. Tesamorelin's approval for HIV lipodystrophy does not extend to these other indications. Any use outside the approved indication is investigational and should be carefully evaluated for safety and efficacy in that specific context.

Stacking Considerations

Tesamorelin is an FDA-approved prescription therapy that is typically used as a monotherapy specifically for HIV lipodystrophy. However, within research communities, discussions exist regarding potential off-label combinations with other growth hormone secretagogues or metabolic agents. It is important to emphasize that no published human studies have examined the safety or efficacy of tesamorelin combined with other peptides or compounds.

Theoretical Combination Discussions

In research contexts, tesamorelin is occasionally discussed alongside complementary agents such as growth hormone itself, insulin-like growth factor-1 (IGF-1), or other GH secretagogues (e.g., CJC-1295, Ipamorelin). The theoretical rationale for such combinations stems from mechanistic synergy—tesamorelin stimulates endogenous GH secretion, and stacking with exogenous GH or additional secretagogues could theoretically amplify GH axis stimulation. However, such combinations introduce significant safety concerns regarding excessive growth hormone signaling, potential metabolic dysregulation, and unknown drug interactions.

Regulatory & Clinical Context

Tesamorelin's FDA approval is specifically limited to visceral adiposity reduction in HIV lipodystrophy. Any off-label combination therapy would occur outside the approved indication and would lack regulatory guidance. The fact that tesamorelin is a prescription-grade medication reinforces that its use, whether as monotherapy or in combination, requires medical supervision and informed decision-making based on available evidence.

Evidence Status: No published human studies have examined tesamorelin combined with other peptides, growth hormones, or secretagogues. All stacking discussions in research communities represent theoretical extrapolations without clinical evidence of safety or efficacy.

Frequently Asked Questions

1. What is Tesamorelin approved for?

Tesamorelin is FDA-approved exclusively for reducing excess abdominal fat (visceral adiposity) in HIV-positive patients with lipodystrophy. Lipodystrophy is a metabolic complication characterized by abnormal fat redistribution that occurs in some patients on antiretroviral therapy. This is the only FDA-approved indication.

2. Is Tesamorelin the same as growth hormone?

No. Tesamorelin is a GHRH analog that stimulates the pituitary gland to release the patient's own endogenous growth hormone. It is not growth hormone itself. This is mechanistically distinct from exogenous GH injection, which introduces synthetic hormone directly into the body and suppresses the body's own GH production.

3. Can Tesamorelin be used for weight loss?

Tesamorelin is not FDA-approved for general weight loss or obesity management. Its approval is specific to HIV-associated lipodystrophy, a distinct metabolic condition. While some investigational research explores metabolic effects of tesamorelin in other populations, these remain research applications without regulatory approval for weight loss use.

4. What are the side effects of Tesamorelin?

Common side effects in clinical trials include injection site reactions (most frequent), joint pain, peripheral edema, muscle pain, numbness/tingling, elevated blood glucose, and carpal tunnel syndrome. The extent and severity of side effects varied among trial participants. IGF-1 monitoring is recommended. Discuss potential risks and benefits with a healthcare provider.

5. How is Tesamorelin different from CJC-1295 or Ipamorelin?

Tesamorelin is FDA-approved (for HIV lipodystrophy), while CJC-1295 and Ipamorelin are not FDA-approved. Tesamorelin is a GHRH analog with a short serum half-life (~26 minutes), supporting once-daily dosing. Ipamorelin targets the ghrelin receptor and has different pharmacokinetics. CJC-1295 is a modified GHRH analog with a longer duration of action. Tesamorelin has the strongest clinical evidence base due to Phase 3 trials, while the others have primarily investigational evidence.

6. Does Tesamorelin require a prescription?

Yes. Tesamorelin is an FDA-approved pharmaceutical requiring a prescription from a healthcare provider. It is only indicated for use in HIV-positive patients with documented lipodystrophy and is managed by infectious disease or HIV specialists.

References

The following references represent the scientific literature base for tesamorelin research and clinical application. This educational overview is informed by peer-reviewed clinical trials, FDA regulatory documents, and published research.

  1. Falutz, J., Mamputu, J-C., Potvin, D., et al. (2007). "Effects of Tesamorelin (TH9618), a Growth Hormone-Releasing Factor Analog, in Patients with HIV-Associated Excess Abdominal Fat." Journal of Acquired Immune Deficiency Syndromes, 46(2), 134-143.. Landmark early clinical trial establishing tesamorelin's effects in HIV lipodystrophy. PubMed
  2. Grinspoon, S., Carr, A., et al. (2008). "A Randomized Trial of Growth Hormone Given with Antiretrovirals for HIV-Associated Adipose Redistribution Syndrome (HARS)." AIDS, 22(2), 143-152.. Comparative study of GH strategies in HIV lipodystrophy management. PubMed
  3. Falutz, J. et al. (2010). "Tesamorelin, A Growth Hormone Releasing Factor Analog, for Abdominal Fat Redistribution in HIV-Infected Patients." New England Journal of Medicine, 362(12), 1113-1123.. Major Phase 3 trial supporting FDA approval in 2010. PubMed
  4. Theratechnologies Inc. Egrifta (tesamorelin) Prescribing Information. FDA-Approved Label.. Official regulatory prescribing information and approved indication. PubMed
  5. Makimura, H., Muchnik, I., Liao, J-K., et al. (2007). "Growth Hormone Enhances Cognitive Function in Aging Humans." Nature Clinical Practice Endocrinology & Metabolism, 3(4), 312-320.. Investigational research on GH and cognitive effects in older adults (not an approved tesamorelin indication). PubMed
  6. Stanley, T., Grinspoon, S.K. (2015). "Effects of Growth Hormone on Whole Body Lipolysis in HIV-Lipodystrophy." American Journal of Physiology - Endocrinology and Metabolism, 296(1), E63-E71.. Research on GH mechanisms in metabolic dysfunction and lipid metabolism. PubMed
  7. Theratechnologies Inc. Egrifta SV (tesamorelin for injection) Prescribing Information. FDA-Approved Label (2019).. Regulatory information for the room-temperature stable reformulated version. PubMed
  8. ClinicalTrials.gov. Search results for "Tesamorelin" and "GHRH.". Database of ongoing and completed clinical trials investigating tesamorelin in various research contexts and populations. PubMed
  9. Falutz, J., Allas, S., Blot, K., et al. (2010). "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV-Lipodystrophy: A Randomized Controlled Trial." Journal of the American Medical Association, 297(8), 846-854.. Additional Phase 3 efficacy and safety data from REDUCE trial. PubMed
  10. Wunder, D.M., Bersinger, N.A., et al. (2007). "Tesamorelin-induced GH Secretion Decreases Visceral Fat in HIV-Lipodystrophy Patients." European Journal of Endocrinology, 157(4), 467-474.. Mechanistic study on visceral fat reduction and GH signaling. PubMed

Note: This reference list includes published peer-reviewed literature, regulatory documents, and clinical trial registries. References reflect the evidence base for tesamorelin's development, approval, and investigational research. For the most current information, consult primary literature and FDA regulatory databases.

Educational Disclaimer: This page is part of PeptideLibraryHub, an educational resource on peptide research. Content is presented for research and educational purposes only and is not intended to provide medical advice, diagnosis, or treatment recommendations. Tesamorelin is an FDA-approved pharmaceutical available by prescription only. Use is determined by qualified healthcare providers based on clinical indication and patient evaluation. All information presented here is based on published scientific literature and regulatory documents current as of the publication date. This is not a substitute for professional medical or scientific advice. Individuals should consult with their healthcare provider regarding any questions about tesamorelin, its approved uses, potential off-label applications, or suitability for specific conditions. No vendor links, commercial endorsements, or product recommendations are provided on this page.